IPCA

IPCA has a long track record of outstanding performance. The sales have grown from Rs. 455 crore in March 2002 to Rs. 3256 crore in March 2015. The EPS has also kept pace. Unfortunately, the US FDA issue has crippled the company. Once that crises is resolved, one can expect IPCA to resume its growth trajectory.

The only uncertainty is that it is not known how long the issue may take to resolve. It could be a couple of months to a year or even longer.

Some analysts have advised that the stock is a good buy at present levels:

The share price of the company corrected 15 per cent in the past one year. However, Nangra of Angel Broking is bullish on IPCA Labs. She says, "IPCA Labs is expected to post a 19.9 per cent CAGR to Rs 4,957 crore and EPS to register a 24.3 per cent CAGR to Rs 45 over FY2015-17E. We think the company's financial will be impacted by the USFDA import alert on the Ratlam facility. For Indore and Silvassa units, the USFDA inspection will take place as and when it is due. While concerns persist, we still maintain our Buy on the stock, on the back of attractive valuations. The share price of the company can touch Rs 810 in the next few quarters."

https://businesstoday.intoday.in/story/healthcare-stocks-you-should-bet-on-long-term-bse/1/219996.html

So, a good strategy may be to buy on dips and average the cost price.